Erfasste Publikationen

2017

Preconditioned intensity-based prostate registration using statistical deformation models
2017 IEEE 14TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI 2017). 2017;40 3: 853-857 (Impact: liegt nicht vor, Typ=Proceedings Paper)
Zettinig O, Rackerseder J, Lentes B, Maurer T, Westenfelder K, Eiber M, Frisch B, Navab N
[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma].
Aktuelle Urol. 2017;48(1): 72-78 (Impact(2016)=0.306, Typ=Review; Journal Article; English Abstract)
Miller K, Bergmann L, Doehn C, Gschwend J, Keilholz U
[PSMA-Radioguided Surgery for Salvage Lymphadenectomy in Recurrent Prostate Cancer].
Aktuelle Urol. 2017;48(2): 148-152 (Impact(2016)=0.306, Typ=Article; Journal Article; English Abstract)
Rauscher I, Eiber M, Maurer T
[The role of immunooncology in the treatment of urothelial cancer].
Aktuelle Urol. 2017; (Impact(2016)=0.306, Typ=Review; Journal Article; English Abstract)
Retz M, Tauber R, Horn T
AUO - Working Society for Urological Oncology Therapy of the muscle invasive Bladder Cancer
Aktuelle Urol. 2017;48(1): 20-22 (Impact(2016)=0.306, Typ=Editorial Material)
Rexer H, Retz M, Albers P
Education in sexual medicine - a nationwide study among German urologists/andrologists and urology residents
Andrologia. 2017;49(2): e12611- (Impact(2016)=1.458, Typ=Article)
Schloegl I, Kohn FM, Dinkel A, Schulwitz H, Gschwend JE, Bosinski HAG, Herkommer K
A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Bajorin D, Galsky MD, Gschwend JE, Tomita Y, Azrilevich A, Witjes F
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Ann Oncol. 2017;28(10): 2481-2488 (Impact(2016)=11.855, Typ=Article; Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II)
Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP
KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Choueiri TK, Powles T, Zhang T, Quinn DI, Gschwend JE, Wan SS, Poehlein C
Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: A Swiss registry
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Mauti LA, Klingbiel D, Schmid S, Bouchaab H, Bartnick T, Gautschi O, Rothschild SI, Loeffler M, Froesch P, Petrausch U, Schild SW, Mingrone W, Peter SP, Prince SS, Pless M, von Moos R, Metaxas Y
Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH)
Ann Oncol. 2017;28 11: 8-8 (Impact(2016)=11.855, Typ=Meeting Abstract)
Mauti L, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Hughes B, Bartnick T, Pavlakis N, Bouchaab H, OByrne K, Rothschild S, Russell P, Prince SS, Thapa B, Pless M, Von Moos R, Metaxas Y, John T
Identification of molecular mechanisms that confer therapy response to CDK4/6 inhibition using a genome-wide CRIPR-dCsa9 gain-of-function screen
Ann Oncol. 2017;28 7: 15-15 (Impact(2016)=11.855, Typ=Meeting Abstract)
Pan Q, Sathe A, Tong Z, Nawroth R
Pembrolizumab +/- chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R, Bae WK, Revesz J, Yamamoto Y, Anido U, Su WP, Fleming M, Markus M, Feng D, Poehlein C, Alva A
Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Retz M, Bedke J, Herrmann E, Grimm MO, Zimmermann U, Muller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Frank M, Gschwend JE
Comparability of programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating immune cells (IC) and tumor cells (TC) in advanced urothelial bladder cancer (UBC) using clinically relevant immunohistochemistry (IHC) assays
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Schwamborn K, Knuchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Ammann J, Weichert W
Results of an open label randomized phase II trial of CV9104, an mRNA-based multivalent cancer immunotherapy in patients (pts) with intermediate or high risk localized prostate cancer (PC) undergoing radical prostatectomy (RPE)
Ann Oncol. 2017;28 5: - (Impact(2016)=11.855, Typ=Meeting Abstract)
Stenzl A, Feyerabend S, Kubler H, Retz M, Grullich C, Hipp M, Klinkhardt U, Hong HS, Doener F, Koch SD, Scholl M, Brutlach S, Schroeder A, Seibel T, Halama N, Schonborn-Kellenberger O, Fotin-Mleczek M, Gnad-Vogt U
Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
Anticancer Res. 2017;37(11): 6437-6442 (Impact(2016)=1.937, Typ=Article; Journal Article; Comparative Study; Observational Study)
Heers H, DE Geeter P, Goebell PJ, Matz U, DE Schultz W, Edlich B, Retz M, Hegele A
Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
Asia Pac J Clin Oncol. 2017;13 4: 129-130 (Impact: liegt nicht vor, Typ=Meeting Abstract)
Mainwaring P, Tannir NM, Powles T, Motzer RJ, Rolland F, Gravis G, Staehler M, Rink M, Retz M, Csoszi T, McCaffrey JA, De Giorgi U, Caserta C, Cheporov S, Gonzalez EE, Duran I, Larkin JG, Berg W, Clary DO, Escudier B, Choueiri TK
PSMA-targeted imaging of prostate cancer: evolution of a success story.
Asian J Androl. 2017;19(3): 388 (Impact(2016)=2.996, Typ=Editorial Material; Journal Article)
Maurer T, Eiber M
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
BJU Int. 2017;119(1): 30-37 (Impact(2016)=4.338, Typ=Journal Article; Journal Article)
Heck MM, Thaler MA, Schmid SC, Seitz AK, Tauber R, Kübler H, Maurer T, Thalgott M, Hatzichristodoulou G, Höppner M, Nawroth R, Luppa PB, Gschwend JE, Retz M
Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
BJU Int. 2017;119(2): 194-195 (Impact(2016)=4.338, Typ=Editorial Material; Comment; Editorial)
Murphy DG, Hofman M, Lawrentschuk N, Maurer T
Value of (111) In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.
BJU Int. 2017;120(1): 40-47 (Impact(2016)=4.338, Typ=Article; Journal Article)
Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller B, Schwaiger M, Gschwend JE, Eiber M, Maurer T
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
BMC Cancer. 2017;17(1): 361 (Impact(2016)=3.288, Typ=Article; Journal Article)
Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, Eiber M, Schwaiger M, Kübler H, Gschwend JE, Combs SE
Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
Clin Nucl Med. 2017;42(7): 547-548 (Impact(2016)=3.64, Typ=Editorial Material; Journal Article)
Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M
Prospective head-to-head comparison ofC-choline-PET/MR andC-choline-PET/CT for restaging of biochemical recurrent prostate cancer.
Eur J Nucl Med Mol Imaging. 2017;44(13): 2179-2188 (Impact(2016)=7.277, Typ=Article; Journal Article)
Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, Beer AJ
Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.
Eur J Nucl Med Mol Imaging. 2017;44(10): 1656-1662 (Impact(2016)=7.277, Typ=Article; Journal Article)
Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs SE, Habl G
What are the Benefits and Harms of Ureteroscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review.
Eur Urol. 2017;72(5): 772-786 (Impact(2016)=16.265, Typ=Review; Journal Article; Review)
Drake T, Grivas N, Dabestani S, Knoll T, Lam T, Maclennan S, Petrik A, Skolarikos A, Straub M, Tuerk C, Yuan CY, Sarica K
Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Eur Urol. 2017;72(3): 461-469 (Impact(2016)=16.265, Typ=Article; Journal Article)
Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF
Tract Sizes in Miniaturized Percutaneous Nephrolithotomy: A Systematic Review from the European Association of Urology Urolithiasis Guidelines Panel.
Eur Urol. 2017;72(2): 220-235 (Impact(2016)=16.265, Typ=Article; Journal Article; Review)
Ruhayel Y, Tepeler A, Dabestani S, MacLennan S, Pet?ík A, Sarica K, Seitz C, Skolarikos A, Straub M, Türk C, Yuan Y, Knoll T
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Eur Urol. 2017;72(5): 828-834 (Impact(2016)=16.265, Typ=Journal Article; Journal Article)
Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM
Anatomical templates of lymph node dissection for upper tract urothelial carcinoma: a systematic review of the literature.
Expert Rev Anticancer Ther. 2017;17(3): 235-246 (Impact(2016)=2.212, Typ=Review; Journal Article; Review)
Campi R, Minervini A, Mari A, Hatzichristodoulou G, Sessa F, Lapini A, Sessa M, Gschwend JE, Serni S, Roscigno M, Carini M
Virotherapy Research in Germany: From Engineering to Translation.
Hum Gene Ther. 2017;28(10): 800-819 (Impact(2016)=4.187, Typ=Review; Journal Article)
Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM
Adenovirus Particle Quantification in Cell Lysates Using Light Scattering.
Hum Gene Ther Methods. 2017;28(5): 268-276 (Impact(2016)=1.831, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't)
Hohl A, Ramms AS, Dohmen C, Mantwill K, Bielmeier A, Kolk A, Ruppert A, Nawroth R, Holm PS
Ga-68-PSMA-PET for Radiation Treatment Planning in Prostate Cancer Recurrences After Surgery: Individualized Medicine or New Standard in Salvage Treatment
Int J Radiat Oncol Biol Phys. 2017;99 S(2): S98-S99 (Impact(2016)=5.133, Typ=Meeting Abstract)
Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE
Prostate cancer-related anxiety in long-term survivors after radical prostatectomy.
J Cancer Surviv. 2017;11(6): 800-807 (Impact: liegt nicht vor, Typ=Article; Journal Article)
Meissner VH, Herkommer K, Marten-Mittag B, Gschwend JE, Dinkel A
Health-related quality of life as a marker of treatment benefit with nivolumab in platinum refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275.
J Clin Oncol. 2017;35 15: - (Impact(2016)=24.008, Typ=Meeting Abstract)
Necchi A, Grimm MO, Retz M, Arija JAA, Bracarda S, Bedke J, Baron AD, Sharma P, Galsky MD, Vaena DA, Kalinka-Warzocha E, Cwikiel M, Pal SK, Morales R, Taylor F, Gooden KM, Plimack ER
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer
J Clin Oncol. 2017;35 15: - (Impact(2016)=24.008, Typ=Meeting Abstract)
Powles T, Gschwend JE, Loriot Y, Bellmunt J, Geczi L, Vulsteke C, Abdelsalam M, Gafanov R, Bae WK, Revesz J, Yamamoto Y, Anido U, Su WP, Fleming MT, Markus M, Feng D, Poehlein CH, Alva A
Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using Ga-PSMA PET/CT.
J Nucl Med. 2017;58(10): 1632-1637 (Impact(2016)=6.646, Typ=Article; Journal Article)
Bieth M, Krönke M, Tauber R, Dahlbender M, Retz M, Nekolla SG, Menze B, Maurer T, Eiber M, Schwaiger M
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
J Nucl Med. 2017;58(Suppl 2): 67S-76S (Impact(2016)=6.646, Typ=Article; Journal Article; Review)
Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL
Detection Efficacy of Hybrid (68)Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.
J Nucl Med. 2017;58(7): 1081-1087 (Impact(2016)=6.646, Typ=Article; Journal Article)
Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M
Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.
J Nucl Med. 2017;58(10): 1617-1623 (Impact(2016)=6.646, Typ=Article; Journal Article; Clinical Trial; Multicenter Study)
Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M
Radiation Dosimetry for (177)Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.
J Nucl Med. 2017;58(3): 445-450 (Impact(2016)=6.646, Typ=Article; Journal Article)
Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
J Nucl Med. 2017;58(2): 235-242 (Impact(2016)=6.646, Typ=Article; Journal Article; Case Reports)
Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ
Solo-Masturbation of 45-year Old Men Depending on Sexual Orientation Identity and Associated Factors: Findings from the German Mals Sex-Study (GMS-Study)
J Sex Med. 2017;14 S(4): E174-E174 (Impact(2016)=2.978, Typ=Meeting Abstract)
Bauer J, Schulwitz H, Albers P, Arsov C, Hadaschik B, Hohenfellner M, Imkamp F, Kuczyk M, Gschwend J, Herkommer K
Surgical Therapy of Peyronies Disease by Partial Plaque Excision and Sealing of Tunical Defect with Collagen Fleece: The Sealing Technique
J Sex Med. 2017;14 1(1): S15-S16 (Impact(2016)=2.978, Typ=Meeting Abstract)
Hatzichristodoulou G, Fiechtner S, Gschwend JE, Lahme S
Prevalence of Erectile Dysfunction in 45-year Old German Men in Association with Risk Factors and Comorbidities-Results of the German Male Sex-Study
J Sex Med. 2017;14 S(4): E127-E127 (Impact(2016)=2.978, Typ=Meeting Abstract)
Herkommer K, Hallanzy J, Kron M, Kohn FM, Albers P, Arsov C, Kuczyk M, Imkamp F, Hadaschik BA, Hohenfellner M, Gschwend JE
First Clinical Evaluation of A New Single Use Flexible Cystoscope Dedicated To Double-J Stent Removal (Isiris-TM)): A European Prospective Multicenter Study
J Urol. 2017;197 S(4): E813-E814 (Impact(2016)=5.157, Typ=Meeting Abstract)
Doizi S, Kamphuis G, Giusti G, Palmero JL, Patterson J, Proietti S, Straub M, de la Rosette J, Traxer O
Erectile Dysfunction in 45-year Old German Men in Association with Risk Factors and Comorbidities; Results of The German Male Sex-Study
J Urol. 2017;197 S(4): E1092-E1093 (Impact(2016)=5.157, Typ=Meeting Abstract)
Herkommer K, Hallanzy J, Kron M, Kohn FM, Schmautz M, Albers P, Arsov C, Hadaschik BA, Hohenfellner M, Imkamp F, Kuczyk M, Gschwend JE
Prostate Cancer-Related Anxiety in Long-Term Survivors After Radical Prostatectomy
J Urol. 2017;197 S(4): E360-E361 (Impact(2016)=5.157, Typ=Meeting Abstract)
Herkommer K, Meissner VH, Dinkel A, Marten-Mittag B, Gschwend JE
Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
J Urol. 2017;197(1): 143-148 (Impact(2016)=5.157, Typ=Article; Journal Article)
Liesenfeld L, Kron M, Gschwend JE, Herkommer K
Evaluation of Recurrent Prostate Cancer after Primary Radiation Therapy As Defined By Phoenix Criteria 68GA-PSMA PET/CT
J Urol. 2017;197 S(4): E1188-E1188 (Impact(2016)=5.157, Typ=Meeting Abstract)
Maurer T, Einspieler I, Rauscher I, Rischpler C, Duwel C, Kronke M, Habl G, Dewes S, Gschwend JE, Wester HJ, Schwaiger M, Eiber M

68GA-PSMA PET/CT for Detection of Early Recurrent Prostate Cancer After Radical Prostatectomy with PSA Values Up To 1ng/ml68
GA-PSMA PET/CT FOR DETECTION OF EARLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY WITH PSA VALUES UP TO 1NG/ML
J Urol. 2017;197 S(4): E1188-E1188 (Impact(2016)=5.157, Typ=Meeting Abstract)
Maurer T, Duwel C, Haller B, Gschwend JE, Schwaiger M, Eiber M
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
JAMA Oncol. 2017;3(1): 68-75 (Impact: liegt nicht vor, Typ=Article; Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study)
de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet. 2017;389(10064): 67-76 (Impact(2016)=47.831, Typ=Article; Journal Article; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't)
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF, IMvigor210 Study Group
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2017;18(3): 312-322 (Impact(2016)=33.9, Typ=Article; Journal Article; Multicenter Study; Clinical Trial, Phase II)
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD
c-Met in chromophobe renal cell carcinoma.
Med Oncol. 2017;34(2): 15 (Impact(2016)=2.634, Typ=Article; Journal Article)
Erlmeier F, Ivanyi P, Hartmann A, Autenrieth M, Wiedemann M, Weichert W, Steffens S
PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Med Oncol. 2017;34(5): 71 (Impact(2016)=2.634, Typ=Article; Journal Article)
Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S
Prognostic impact of PD-1 and its ligands in renal cell carcinoma.
Med Oncol. 2017;34(6): 99 (Impact(2016)=2.634, Typ=Review; Journal Article; Review)
Erlmeier F, Weichert W, Schrader AJ, Autenrieth M, Hartmann A, Steffens S, Ivanyi P
Efficacy update of Nivolumab monotherapy in patients with metastatic or surgically unresectable locally advanced urothelial carcinoma who have received prior platinum-based treatment: phase II CheckMate 275 study
ONCOLOGY RESEARCH AND TREATMENT. 2017;40 3: 114-115 (Impact(2016)=1.667, Typ=Meeting Abstract)
Bedke J, Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Grullich C, von Amsberg G, Steiner T, Saci A, Lambert A, Azrilevich A, Galsky MD
Preface
ONCOLOGY RESEARCH AND TREATMENT. 2017;40 2: 1-1 (Impact(2016)=1.667, Typ=Editorial Material)
Gschwend JE, Miller K
First-line Therapy of non-mild or mild symptomatic metastatic castration-resistant Prostate Carcinoma
ONCOLOGY RESEARCH AND TREATMENT. 2017;40 2: 4-5 (Impact(2016)=1.667, Typ=Article)
Gschwend JE
Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy
ONCOLOGY RESEARCH AND TREATMENT. 2017;40 3: 115-115 (Impact(2016)=1.667, Typ=Meeting Abstract)
von Amsberg G, Perez-Garcia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz M, Niegisch G, Duran I, Theodore C, Grande E, Thastrom AC, Li S, Abidoye OO, Van Der Heijden MS, Lunenburg Lymphoma Phase I II
11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer.
Oncotarget. 2017;8(39): 66516-66527 (Impact(2016)=5.168, Typ=Article; Journal Article)
Wieder H, Beer AJ, Holzapfel K, Henninger M, Maurer T, Schwarzenboeck S, Rummeny EJ, Eiber M, Stollfuss J
Treatment algorithms for testicular cancer
Onkologie. 2017;23(2): 87-88 (Impact: liegt nicht vor, Typ=Editorial Material)
Gschwend JE
Malignant Testicular Tumors An Example of interdisciplinary Oncology
Onkologie. 2017;23(2): 84-86 (Impact: liegt nicht vor, Typ=Editorial Material)
Gschwend JE, Classen J, Bokemeyer C, Hoffken K
68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
Prostate. 2017;77(8): 920-927 (Impact(2016)=3.82, Typ=Article; Journal Article)
Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE
Predictors of prostate cancer-related anxiety in long-term survivors after radical prostatectomy
Psychooncology. 2017;26 3: 83-83 (Impact(2016)=3.095, Typ=Meeting Abstract)
Dinkel A, Meissner V, Marten-Mittag B, Gschwend J, Herkommer K
Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis.
Radiat Oncol. 2017;12(1): 2 (Impact(2016)=2.568, Typ=Article; Journal Article)
Hegemann NS, Schlesinger-Raab A, Ganswindt U, Hörl C, Combs SE, Hölzel D, Gschwend JE, Stief C, Belka C, Engel J
[PET-CT and PET-MRI of the prostate : From F-FDG to Ga-PSMA].
Radiologe. 2017;57(8): 631-636 (Impact(2016)=0.404, Typ=Article; Journal Article; Review)
Knorr K, Eiber M, Maurer T, Wester HJ, Scheidhauer K
Non-invasive imaging of engineered human tumors in the living chicken embryo.
Sci Rep. 2017;7(1): 4991 (Impact(2016)=4.259, Typ=Article; Journal Article)
Jefferies B, Lenze F, Sathe A, Truong N, Anton M, von Eisenhart-Rothe R, Nawroth R, Mayer-Kuckuk P
Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer.
Sci Rep. 2017;7(1): 395 (Impact(2016)=4.259, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't)
Seitz AK, Christensen LL, Christensen E, Faarkrog K, Ostenfeld MS, Hedegaard J, Nordentoft I, Nielsen MM, Palmfeldt J, Thomson M, Jensen MT, Nawroth R, Maurer T, Ørntoft TF, Jensen JB, Damgaard CK, Dyrskjøt L
Oligometastases from Prostate Cancer: local treatment with stereotactic body radiotherapy (SBRT)
Strahlenther Onkol. 2017;193 1: S69-S70 (Impact(2016)=2.735, Typ=Meeting Abstract)
Habl G, Straube C, Duma MN, Oechsner M, Kessel KA, Gschwend JE, Combs SE
Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after Ga-68-PSMA-PET imaging
Strahlenther Onkol. 2017;193 1: S135-S135 (Impact(2016)=2.735, Typ=Meeting Abstract)
Schiller K, Eiber M, Maurer T, Combs SE, Habl G
PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?
Theranostics. 2017;7(7): 2046-2047 (Impact(2016)=8.712, Typ=Editorial Material; Comment; Editorial)
Maurer T, Murphy DG, Hofman MS, Eiber M
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
Trials. 2017;18(1): 457 (Impact(2016)=1.969, Typ=Article; Journal Article)
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Stöckle M
Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin.
Urol Oncol. 2017;35(9): 544.e1-544.e10 (Impact(2016)=3.767, Typ=Article; Journal Article)
Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck SM, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M, German Bladder Cancer Network , Nawroth R
Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.
Urol Oncol. 2017;35(9): 544.e11-544.e23 (Impact(2016)=3.767, Typ=Article; Journal Article)
Skowron MA, Sathe A, Romano A, Hoffmann MJ, Schulz WA, van Koeveringe GA, Albers P, Nawroth R, Niegisch G
[Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].
Urologe A. 2017;56(1): 40-43 (Impact(2016)=0.289, Typ=Article; Journal Article; Clinical Trial)
Autenrieth ME, Horn T, Kurtz F, Nguyen K, Morgenstern A, Bruchertseifer F, Schwaiger M, Blechert M, Seidl C, Senekowitsch-Schmidtke R, Gschwend JE, Scheidhauer K
[Significance of PSMA imaging in prostate cancer].
Urologe A. 2017;56(1): 3-12 (Impact(2016)=0.289, Typ=Article; Journal Article; Randomized Controlled Trial)
Gasch C, Düwel C, Kopka K, Kratochwil C, Vinsensia M, Eiber M, Maurer T, Haberkorn U, Hadaschik B, Giesel FL
[Side effects of chemotherapy].
Urologe A. 2017;56(4): 472-479 (Impact(2016)=0.289, Typ=Article; Journal Article)
Hauner K, Maisch P, Retz M
[PSMA-targeted radioligand therapy in prostate cancer].
Urologe A. 2017;56(1): 32-39 (Impact(2016)=0.289, Typ=Article; Journal Article; Review)
Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M
[Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics].
Urologe A. 2017;56(2): 202-207 (Impact(2016)=0.289, Typ=Article; Journal Article; Review)
Hofbauer S, Kalogirou C, Roghmann F, Seitz AK, Vallo S, Wezel F, Worst T, Nawroth R
[PSMA-radioguided surgery in localised recurrent prostate cancer].
Urologe A. 2017;56(11): 1417-1423 (Impact(2016)=0.289, Typ=Article; Journal Article; Review; English Abstract)
Horn T, Rauscher I, Eiber M, Gschwend JE, Maurer T
[Innovative radionuclide use in urology].
Urologe A. 2017;56(1): 1-2 (Impact(2016)=0.289, Typ=Editorial Material; Editorial; Introductory Journal Article)
Maurer T, Gschwend JE, Schwaiger M, Eiber M
[Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Urologe A. 2017;56(9): 1185-1186 (Impact(2016)=0.289, Typ=Editorial Material; Journal Article)
Ohlmann CH, Miller K, Gschwend J
[PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects].
Urologe A. 2017;56(1): 18-23 (Impact(2016)=0.289, Typ=Article; Journal Article; Review)
Rauscher I, Eiber M, Jilg CA, Gschwend JE, Maurer T
[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of
Urologe A. 2017;56(10): 1331-1332 (Impact(2016)=0.289, Typ=Editorial Material; Journal Article; Review)
Rexer H, Ohlmann CH, Gschwend J, AUO
[First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metas
Urologe A. 2017;56(5): 659-661 (Impact(2016)=0.289, Typ=Editorial Material; Journal Article)
Rexer H, Ohlmann CH, Retz M
[Sexual medicine in daily practice : Germany-wide questionnaire of urologists].
Urologe A. 2017;56(5): 637-644 (Impact(2016)=0.289, Typ=Article; Journal Article)
Schloegl I, Koehn FM, Beier KM, Bosinski HAG, Dinkel A, Gschwend JE, Herkommer K
[The 6th symposium of the German Association for Bladder Cancer Research].
Urologe A. 2017;56(6): 806-807 (Impact(2016)=0.289, Typ=Editorial Material; Journal Article)
Schulz WA, Kramer MW, Fuessel S, Stöhr R, Hoffmann MJ, Nawroth R
[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Urologe A. 2017;56(1): 24-31 (Impact(2016)=0.289, Typ=Article; Journal Article)
Tauber R, Gschwend J, Scheidhauer K, Eiber M, Krönke M
First clinical evaluation of a new single-use flexible cystoscope dedicated to double-J stent removal (Isiris(TM)): a European prospective multicenter study.
World J Urol. 2017;35(8): 1269-1275 (Impact(2016)=2.743, Typ=Article; Journal Article; Multicenter Study)
Doizi S, Kamphuis G, Giusti G, Palmero JL, Patterson JM, Proietti S, Straub M, de la Rosette J, Traxer O

2015

(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.
Abdom Imaging. 2015;40(6): 1769-71 (Impact(2014)=1.63, Typ=Article; Journal Article)
Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M
Miniperc and retrograde intrarenal surgery: when and how?
Actas Urol Esp. 2015;39(7): 442-50 (Impact: liegt nicht vor, Typ=Review; Journal Article)
Ramón de Fata F, Hauner K, Andrés G, Angulo JC, Straub M
[In Process Citation].
Aktuelle Urol. 2015;46(2): 159-71; quiz 172-3 (Impact(2014)=0.162, Typ=Journal Article)
Gschwend J
Ileum-Neoblase nach Hautmann.
Aktuelle Urol. 2015;46(2): 160-171 (Impact(2014)=0.162, Typ=Article)
Gschwend J

[In Process Citation].
Aktuelle Urol. 2015;46(4): 271-2 (Impact(2014)=0.162, Typ=Editorial Material; Journal Article; Comment)
Gschwend JE
[In Process Citation].
Aktuelle Urol. 2015;46(2): 103 (Impact(2014)=0.162, Typ=Editorial Material; News)
Maurer T, Protzel C, Gschwend JE, Rexer H
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Aktuelle Urol. 2015;46(2): 151-7 (Impact(2014)=0.162, Typ=Review; Journal Article; English Abstract)
Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend J, Kuczyk M
Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
Anticancer Res. 2015;35(10): 5679-85 (Impact(2014)=1.826, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't)
Thalgott M, Rack B, Horn T, Heck MM, Eiber M, Kübler H, Retz M, Gschwend JE, Andergassen U, Nawroth R
International multicentre psychometric evaluation of patient-reported outcome data for the treatment of Peyronie's disease.
BJU Int. 2015;115(5): 822-8 (Impact(2014)=3.533, Typ=Article; Journal Article; Multicenter Study)
Kueronya V, Miernik A, Stupar S, Kojovic V, Hatzichristodoulou G, Egydio P, Tosev G, Falcone M, De Luca F, Mulalic D, Djordjevic M, Schoenthaler M, Fahr C, Kuehhas F
Peyronies disease following radical prostatectomy: Incidence in a population with formal pre operative assessment
BJU Int. 2015;116 2: 32-32 (Impact(2014)=3.533, Typ=Meeting Abstract)
Sullivan JF, Tal R, Heck M, Bernstein M, Nelson CJ, Mulhall JP
Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.
BMC Cancer. 2015;15: 455 (Impact(2014)=3.362, Typ=Article; Journal Article; Clinical Trial, Phase III; Multicenter Study)
Retz M, de Geeter P, Goebell PJ, Matz U, de Schultz W, Hegele A
Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
BMC Cancer. 2015;15: 458 (Impact(2014)=3.362, Typ=Article; Journal Article; Clinical Trial)
Thalgott M, Rack B, Eiber M, Souvatzoglou M, Heck MM, Kronester C, Andergassen U, Kehl V, Krause BJ, Gschwend JE, Retz M, Nawroth R
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer.
BMC Med. 2015;13: 201 (Impact(2014)=7.356, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural)
Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK
Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.
Cancer Biol Ther. 2015;16(10): 1526-34 (Impact(2014)=3.072, Typ=Article; Journal Article)
Fazel J, Rötzer S, Seidl C, Feuerecker B, Autenrieth M, Weirich G, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.
Cancer Causes Control. 2015;26(11): 1603-16 (Impact: liegt nicht vor, Typ=Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural)
Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, PRACTICAL consortium , Lathrop M, Smith GD, Martin RM, Cook M, Morgan A, Lophatananon A, Fisher C, Leongamornlert D, Saunders EJ, Sawyer EJ, Govindasami K, Tymrakiewicz M, Guy M, Livni N, Wilkinson R, Jugurnauth-Little S, Hazel S, Dadaev T, Southey MC, Fitzgerald LM, Pedersen J, Hopper J, Karlsson A, Cavalli- Bjoerkman C, Johansson JE, Adolfson J, Aly M, Broms M, Stattin P, Henderson BE, Schumacher F, Auvinen A, Taari K, Maeaettaenen L, Kujala P, Murtola T, Tammela TL, Wahlfors T, Roder A, Iversen P, Klarskov P, Nielsen SF, Key TJ, Wallinder H, Gustafsson S, Donovan JL, Hamdy F, Cox A, George A, Lane A, Marsden G, Davis M, Brown P, Pharoah P, Signorello LB, Zheng W, McDonnell SK, Schaid DJ, Wang L, Tillmans L, Riska S, Schnoeller T, Herkommer K, Luedeke M, Vogel W, Wokozorczyk D, Lubiski J, Kluzniak W, Butterbach K, Stegmaier C, Holleczek B, Zachariah B, Lim HY, Park H, Haley J, Pow-Sang J, Rincon M, Radlein S, Sellers T, Slavov C, Vlahova A, Mitkova A, Kachakova D, Popov E, Christova S, Dikov T, Mitev V, Eckert A, Spurdle A, Collins A, Wood G, Malone G, Clements JA, Kerr K, Turner M, Saunders P, Heathcote P, Srinivasan S, Moya L, Yeadon T, Santos J, Jerónimo C, Paulo P, Pinto P, Henrique R, Maia S, Michael A, Kierzek A, Wu H
A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.
Cancer Discov. 2015;5(4): 368-79 (Impact(2014)=19.453, Typ=Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural)
Stegeman S, Amankwah E, Klein K, O'Mara TA, Kim D, Lin HY, Permuth-Wey J, Sellers TA, Srinivasan S, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pharoah P, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Kaneva R, Teixeira MR, PRACTICAL Consortium , Australian Prostate Cancer BioResource , Spurdle AB, Clements JA, Park JY, Batra J, Cook M, Morgan A, Lophatananon A, Fisher C, Leongamornlert D, Saunders EJ, Sawyer EJ, Govindasami K, Tymrakiewicz M, Guy M, Livni N, Wilkinson R, Jugurnauth-Little S, Hazel S, Dadaev T, Pedersen J, Hopper JL, Southey MC, Karlsson A, Cavalli-Bjoerkman C, Johansson JE, Adolfson J, Aly M, Broms M, Stattin P, Henderson BE, Schumacher F, Auvinen A, Taari K, Maeaettaenen L, Kujala P, Murtola T, Tammela TL, Wahlfors T, Roder A, Iversen P, Klarskov P, Nielsen SF, Weischer M, Key TJ, Wallinder H, Gustafsson S, Donovan JL, Hamdy F, George A, Lane A, Marsden G, Davis M, Brown P, Pashayan N, Holt S, Signorello LB, Zheng W, Wang L, Tillmans L, Riska S, Rinckleb A, Herkommer K, Luedeke M, Wokozorczyk WV, Lubiski J, Kluzniak W, Dieffenbach Ak, Stegmaier C, Arndt V, Zachariah B, Park H, Pow-Sang J, Rincon M, Radlein S, Vlahova A, Mitkova A, Slavov C, Kachakova D, Popov E, Christova S, Dikov T, Mitev V, Lose F, Santos J, Barros-Silva J, Paulo P, Pinto P, Henrique R, Maia S, Risbridger G, Taylor R, Tilley W, Butler L, Horvath L, O'Brien C, Yeadon T, Eckert A, Wood G, Heathcote P, Malone G, Kerr K, Turner M, Collins A
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.
Cancer Epidemiol Biomarkers Prev. 2015;24(7): 1121-9 (Impact(2014)=4.125, Typ=Article; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural)
Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR, Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA, Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF, Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L, Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA, Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW, Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D, Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E, Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z, Eeles RA, Easton DF, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology , UK ProtecT Study Collaborators , PRACTICAL Consortium , John E, Joshi A, Shahabi A, Dickinson JL, Marthick JR, Stern MC, Wallace DM, Doherty A, Bhatt RI, ubramonian K, Arrand J, Flanagan L, Bradley SA, Bollina P, Bradshaw L, Catto J, Cooper D, Down L, Doble A, Doherty A, Durkan G, Elliott E, Gillatt D, Herbert P, Holding P, Howson J, Jones M, Kockelbergh R, Kumar R, Holding P, Kynaston H, Lane A, Lennon T, Lyons N, Leung H, Mason M, Moody H, Powell P, Paul A, Prescott S, Rosario D, O'Sullivan P, Thompson P, Bradshaw L, Tidball S, Brown PM, George A, Marsden G, Lane A, Davis M, Edwards S, Fisher C, Jameson C, Page E, Pedersen J, Aitken J, Gardiner RA, Srinivasan S, Lose F, Kedda MA, Alexander K, O'Mara T, Risbridger G, Tilley W, Horvarth L, Heathcote P, Wood G, Malone G, Samaratunga H, Saunders P, Eckert A, Yeadon T, Kerr K, Collins A, Turner M, Foote SJ, Marthick JR, Polanowski A, McWhirter RM, Dwyer T, Blizzard CL, Popov E, Kachakova D, Mitkova A, Stancheva TG, Beltcheva O, Dodova R, Vlahova A, Dikov T, Christova S, Borre M, Klarskov P, Nielsen SF, Iversen P, Røder A, Bojesen SE, Dieffenbach AK, Luedeke M, Schrader M, Hoegel J, Vogel W, Määttänen L, Tammela T, Auvinen A, Tillmans L, Riska S, Wang L, Stram D, Kolonel LN, Pow-Sang J, Park HY, Radlein S, Rincon M, Zachariah B
Genome-wide association study of prostate cancer-specific survival.
Cancer Epidemiol Biomarkers Prev. 2015;24(11): 1796-800 (Impact(2014)=4.125, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't)
Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubi?ski J, Klu?niak W, Cannon-Albright L, Brenner H, Herrmann V, Holleczek B, Park JY, Sellers TA, Lim HY, Slavov C, Kaneva RP, Mitev VI, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, PRACTICAL consortium , Batra J, Clements JA, Australian Prostate Cancer BioResource , Albanes D, Andriole GL, Berndt SI, Chanock S, Gapstur SM, Giovannucci EL, Hunter DJ, Kraft P, Le Marchand L, Ma J, Mondul AM, Penney KL, Stampfer MJ, Stevens VL, Weinstein SJ, Trichopoulou A, Bueno-de-Mesquita BH, Tjønneland A, Cox DG, BPC3 consortium , Maehle L, Schleutker J, Lindström S, Wiklund F
WITHDRAWN: Immunotherapy for advanced renal cell cancer.
Cochrane Database Syst Rev. 2015;(12): CD001425 (Impact(2014)=6.035, Typ=Journal Article; Review; Meta-Analysis)
Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt TJ
[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery.
EJNMMI Res. 2015;5(1): 68 (Impact: liegt nicht vor, Typ=Article; Journal Article)
Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ
Comparison of [11C]Choline and [18F]Galacto-RGD as pharmacodynamic biomarker for therapy response assessment of avastin therapy in a PC-3 Prostate Cancer Xenograft Model
Eur J Nucl Med Mol Imaging. 2015;42 1: S261-S262 (Impact(2014)=5.383, Typ=Meeting Abstract)
Schwarzenbock S, Souvatzoglou M, Heuschkel M, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester H, Beer AJ, Krause BJ
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Eur Urol. 2015;68(2): 317-24 (Impact(2014)=13.938, Typ=Article; Journal Article; Multicenter Study)
Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.
Eur Urol. 2015;67(5): 904-12 (Impact(2014)=13.938, Typ=Review; Journal Article)
Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B
Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.
Eur Urol. 2015;68(3): 530-4 (Impact(2014)=13.938, Typ=Article; Journal Article)
Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kübler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend JE, Eiber M
Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
Eur Urol. 2015;67(4): 750-63 (Impact(2014)=13.938, Typ=Article; Journal Article)
Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Pet?ík A, Türk C
Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes.
Histochem Cell Biol. 2015;144(2): 147-56 (Impact(2014)=3.054, Typ=Article; Journal Article)
Erlmeier F, Feuchtinger A, Borgmann D, Rudelius M, Autenrieth M, Walch AK, Weirich G
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Hum Mol Genet. 2015;24(19): 5589-602 (Impact(2014)=6.393, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural)
Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Woko?orczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA, PRACTICAL Consortium , COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative , Australian Prostate Cancer BioResource , UK Genetic Prostate Cancer Study Collaborators , UK ProtecT Study Collaborators , Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z, Cook M, Morgan A, Lophatananon A, Fisher C, Sawyer EJ, Tymrakiewicz M, Livni N, Wilkinson R, Jugurnauth-Little S, Hazel S, Severi G, Pedersen J, Southey MC, Fitzgerlad LM, Hopper JL, Karlsson A, Cavalli-Bjoerkman C, Johansson JE, Adolfson J, Aly M, Broms M, Stattin P, Henderson BE, Schumacher F, Auvinen A, Taari K, Maeaettaenen L, Kujala P, Murtola T, Tammela TL, Wahlfors T, Weischer M, Roder A, Iversen P, Klarskov P, Nielsen SF, Key TJ, Wallinder H, Gustafsson S, Donovan JL, Hamdy F, Cox A, George A, Lane A, Marsden G, Davis M, Brown P, Pharoah P, Holt S, Signorello LB, Zheng W, McDonnell SK, Schaid DJ, Wang L, Tillmans L, Riska S, Rinckleb A, Herkommer K, Luedeke M, Vogel W, Wokozorczyk D, Lubinski J, Kluzniak W, Stegmaier C, Zachariah B, Lim HY, Park H, Haley J, Pow-Sang J, Rincon M, Radlein S, Sellers T, Vlahova A, Mitkova A, Slavov C, Kachakova D, Popov E, Christova S, Dikov T, Mitev V, Eckert A, Spurdle A, Collins A, Wood G, Malone G, Clements JA, Alexander K, Kerr K, Kedda MA, Turner M, Saunders P, Heathcote P, Srinivasan S, Omara T, Yeadon T, Santos J, Barros-Silva J, Paulo P, Pinto P, Henrique R, Maia S, Michael A, Kierzek A, Wu H, Abbasi Z, Abdul-Hamid MA, Abel PD, Abrams PH, Adab FA, Adamson A, Adeyoju A, Afzal N, Ahiaku EK, Ahmed M, Al Sudani ML, Alcock C, Ali Z, Almond DJ, Alonzi R, Al-Samarraie AS, Al-Samerraie , Al-Singary W, Al-Sudani , Anderson J, Andrews S, Andrews H, Anjum I, Anson K, Anyamene NA, Apakama I, Aparcia F, Archbold JA, Ash D, Ashford RF, Azzabi A, Badenoch D, Bahl A, Bailey MJ, Bailey K, Ball AJ, Banerjee G, Barber N, Barber J, Baria , Barnes DG, Bashir J, Basu P, Bates CA, Bax NA, Baxter-Smith D, Bdesha A, Beacock CJ, Beaney RP, Beard R, Beatty JD, Beck R, Beese G, Beesley S, Bell CR, Bellringer J, Benson R, Beresford , Bevis CR, Bhana R, Bhanot S, Bhatnagar A, Bhatt RI, Birch B, Birtle A, Bishop M, Biyani CS, Blacklock AR, Blades R, Bliss P, Bloomfield DJ, Boddy S, Booth CM, Bose P, Bott MC, Bottomley D, Boucher NR, Bowen J, Bower M, Bowsher WG, Boyd PJ, Bramble FJ, Brewster SF, Briggs T, Brock C, Brock S, Bromage S, Brough R, Brown R, Brown S, Brown R, Browning TJ, Bryan N, Burgess NA, Burns-Cox N, Butterworth PC, Cahill D, Callaghan PS, Calleary J, Calleja M, Calman F, Camilleri P, Campbell A, Cannon A, Carnell DM, Carr TW, Carter S, Carter CJ, Carter AC, Castle BM, Chadwick D, Chahal R, Chakraborti P, Chappell , Charig C, Chetiyawardana AD, Chilton C, Chinegwundoh FI, Chong I, Choudhury A, Chow WM, Christmas TJ, Churn MJ, Clarke NW, Clavijo-Eisele J, Coe M, Cohen NP, Coker C, Cole T, Cole DJ, Cole O, Collins G, Collinson M, Conn I, Connell C, Cook A, Cooke P, Cooksey G, Coombs L, Copland RF, Cornaby AJ, Cornford PA, Corolis , Corr J, Costello CB, Coull MN, Cowan R, Cox R, Coyle C, Crew J, Crisp JC, Cross W, Cross W, Cruger D, Crundwell M, Cummings , Dahar N, Daniel FN, Darrad J, Daruwala P, Das G, Datta S, Davidson S, Davies J, Davison OW, Dawkins G, Dawson C, De Bolla AR, Dearnaley D, Desai KM, Deutsch GP, Dick J, Dickinson AJ, Dickson J, Dinneen M, Dixit S, Dobbs HJ, Doble A, Dodds D, Doherty A, Donaldson P, Dooldeniya M, Douglas SF, Drake , Duchesne GM, Duffy P, Dunn M, Dunsmuir WD, Durrani SK, Eaton AC, Eccles D, Eddy B, Eden CD, Edwards J, Elkabir J, Elliott PT, Ellis BW, Ellis R, El-Modir A, Elves AW, Elwell C, Emberton M, Emmerson L, England RC, Errington RD, Evans DG, Falconer A, Fawcett D, Featherston C, Featherstone CJ, Feggetter J, Ferguson C, Fermont D, Ferro M, Fletcher M, Folkes A, Ford TF, Foster PW, Franks KN, Frim O, Gale J, Gallegos C, Gelister JS, Ghana , Gibbs S, Gilbert H, Gillatt D, Glaholm J, Glass JM, Glenister J, Goode TD, Gordon EM, Gower RL, Graham J, Green D, Greenland J, Grieve R, Griffiths TR, Gujral S, Gupta N, Gurun RM, Guy PJ, Haldar N, Halder N, Hamdy FC, Hamilton C, Hammonds J, Hampson SJ, Hanbury DC, Hardman PD, Harland SJ, Harney JM, Harper P, Harris S, Harris D, Harrison GS, Harriss DR, Harvey-Hills N, Hawkyard S, Heath CM, Hehir M, Hellawell GO, Hendry D, Henley M, Henry A, Hetherington J, Hickish T, Hicks JA, Hilman S, Hindley R, Hindmarsh JR, Hines J, Hingorani M, Ho ET, Hodgson S, Hoffman U, Holden D, Hollingdale A, Hollins GW, Holmes SA, Horan G, Horwich A, Hoskin P, Howell GP, Hrouda D, Huddart R, Hudson L, Hughes R, Hughes M, Hughes O, Humber C, Iacovou JW, Ibrahim A, Inglis JA, Irving S, Irwin C, Izatt L, Izegbu V, Jameel B, James MJ, James N, James RL, Javle P, Jenkins P, Jhavar S, Jones G, Jones CR, Jones DA, Joseph J, Joss S, Kaisary A, Kaliski AL, Kapur G, Karim O, Karp SJ, Keeley FX, Kelkar AR, Kelleher JP, Kelly J, Kenwrick S, Khan F, Khoo V, Kimber RM, Kinder R, Kirby RS, Kirk D, Kirkbride P, Kirollos MM, Kockelbergh R, Koenig PC, Kooiman GG, Koreich O, Koupparis A, Kourah M, Kraus S, Kujawa ML, Kulkarni R, Kumar M, Kunkler IH, Kynaston H, Lachlan KL, Laing R, Lalloo F, Lancashire M, Langley SE, Laniado M, Larner TR, Lau MW, Lawrence WT, Lawson A, Le Roux PJ, Leader M, Lee JO, Lee L, Lee A, Lemburger RJ, Leone P, Lester J, Leung H, Lewis J, Lewis DC, Liston T, Livsey J, Lloyd S, Locke I, Lodge R, Logue J, Longmuir M, Lucas MG, Luscombe CJ, Lydon A, Lynch M, Lynn NN, MacDermott JP, Macdonagh RP, Macdonald , Madaan S, Madhava KR, Maguire J, Maher ER, Mahmood R, Mair GH, Malone PR, Mangar SA, Mantle M, Mark I, Mason R, Mason MD, Matanhelia , Matenhelia S, Matthews PN, McAleese J, McBride D, McFarlane J, McGrath , McIlhenny C, McInerney P, McIntosh G, McKinna F, McLaren D, McLarty E, McMenemin R, McNeill A, McNicholas TA, Meddings RN, Mee AD, Melcher L, Memon , Menzes P, Miller M, Mills R, Mitchell S, Mithal N, Mitra A, Mobb GE, Moffat LE, Mokete , Money-Kyrle J, Montgomery B, Moody MP, Morley R, Morris SB, Morrison P, Mort D, Mostafid AH, Motiwala H, Mufti G, Muir G, Mumtaz F, Murphy M, Murray KW, Murray A, Murrell S, Muthukumar D, Naerger H, Namasivayam S, Nargund V, Nawrocki , Neilson D, Nethersell A, Barwell J, Newby JC, Newman H, Newton R, Oakley N, O'Boyle PJ, O'Brien J, O'Brien TS, O'Donnell H, O'Donoghue N, O'Donoghue E, Ogden C, Ohja H, Oliver T, Ong EK, O'Reilly P, O'Rourke JS, Osborn D, Ostler P, O'Sullivan J, Owen J, Palfrey E, Panades M, Panakis N, Pancharatnam M, Pantelides ML, Panwar U, Parikh O, Parker C, Parker CH, Parys BT, Pascoe S, Patel A, Paterson J, Pathack S, Pati J, Patterson H, Pattu , Paul A, Payne H, Peake D, Pedley I, Pengelly A, Peracha AM, Perry M, Persad R, Peters J, Philp NH, Philp T, Pickering LM, Pigott K, Plail R, Plowman PN, Pocock RD, Pope AJ, Popert R, Porter T, Potter JM, Powell C, Powles TB, Prasad K, Prasad SS, Prejbisz JW, Prescott S, Protheroe A, Qureshi KN, Raby N, Ragavan N, Raju PG, Ramachandra PB, Raman R, Rane A, Rankin J, Rao Y, Ratan HL, Ravi R, Ravishankar K, Read , Reddy PJ, Rimington PR, Ritchie PA, Roberts JT, Robertson A, Robinson A, Robinson AC, Robinson LQ, Rochester MA, Rogers PB, Rosenbaum TP, Rothwell N, Rowbotham C, Rowe , Rowley K, Ruddy D, Rundle J, Russell JM, Ryan PG, Sabharwal A, Saggar AK, Samanci A, Sangar VK, Saxby MF, Schwaibold H, Scoble JE, Scrase C, Selim , Sells H, Sethia KK, Shackley DC, Shaffer , Shah N, Shakespeare D, Shanley S, Sharma NK, Sheehan DJ, Sherwin E, Shum PL, Side L, Sidek N, Sikora K, Simcock R, Sinclair AM, Singh P, Siva M, Smith MF, Smith J, Sokal M, Sole GM, Speakman MJ, Spiers A, Sreenivasan T, Srihari NN, Srinivasan , Sriram R, Staffurth JN, Stewart D, Stockdale A, Stott MA, Stower MJ, Strachan JR, Stuart NS, Sugden E, Summerton D, Sundar S, Sundaram SK, Suresh G, Susnerwala S, Swami KS, Symons SJ, Syndikus I, Tahir S, Tanquay J, Taylor JW, Taylor JW, Terry T, Thomas RJ, Thomas SA, Thompson A, Thomson AH, Thurston A, Tilsley O, Tindall SF, Tipples K, Tong , Toussi H, Toy EW, Trembath RC, Tulloch DN, Turner KJ, Tweedle J, Tyrell CJ, Umez-Eronini N, Urwin GH, Vale JA, Van As , Van As N, Vasanthan S, Vesey S, Vilarino-Varela M, Violet J, Virdi J, Wade R, Waite K, Walker EM, Walker R, Wallace DM, Watkin NA, Watson ME, Waxman JH, Waymont B, Weaver A, Webb RJ, Wedderburn A, Wells P, Wemyss-Holden GD, Weston PM, Wheatley D, Whelan P, Whillis D, Wilde AD, Wiles V, Wilkins M, Williams JH, Williams S, Willis M, Wills MI, Wilson R, Wilson JR, Winkler MH, Wise M, Woodhams S, Woodhouse C, Woodward C, Woolf , Woolfenden KA, Worlding J, Wright M, WYLIE , Wylie JP, Wynne C, Zang A, Zarkar A, Cox A, Brown PM, George A, Marsden G, Lane A, Davis M, Bollina P, Bonnington S, Bradshaw L, Catto J, Cooper D, Down L, Doble A, Doherty A, Durkan G, Elliott E, Gillatt D, Herbert P, Holding P, Howson J, Jones M, Kockelbergh R, Kumar R, Kynaston H, Lane A, Lennon T, Lyons N, Leung H, Mason M, Moody H, Powell P, Paul A, Prescott S, Rosario D, O'Sullivan P, Thompson P, Tidball S
Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study.
Infect Agent Cancer. 2015;10: 31 (Impact(2014)=2.358, Typ=Article; Journal Article)
Schmid SC, Thümer L, Schuster T, Horn T, Kurtz F, Slotta-Huspenina J, Seebach J, Straub M, Maurer T, Autenrieth M, Kübler H, Retz M, Protzer U, Gschwend JE, Hoffmann D
Multimodal image-guided prostate fusion biopsy based on automatic deformable registration.
Int J Comput Assist Radiol Surg. 2015;10(12): 1997-2007 (Impact(2014)=1.707, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't)
Zettinig O, Shah A, Hennersperger C, Eiber M, Kroll C, Kübler H, Maurer T, Milletarì F, Rackerseder J, Schulte Zu Berge C, Storz E, Frisch B, Navab N
Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
J Cancer Res Clin Oncol. 2015;141(8): 1457-64 (Impact(2014)=3.081, Typ=Article; Journal Article; Clinical Trial; Research Support, Non-U.S. Gov't)
Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE, Andergassen U, Nawroth R
First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial
J Clin Oncol. 2015;33 S(15): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Bellmunt J, Eigl BJ, Senkus-Konefka E, Loriot Y, Twardowski P, Castellano DE, Blais N, Sridhar SS, Sternberg CN, Retz M, Blumenstein BA, Jacobs C, Stewart PS, Petrylak DP
Response to vinflunine treatment after prior platinum-based chemotherapy in patients with advanced urothelial carcinoma independent of primary tumor location
J Clin Oncol. 2015;33 S(15): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Hegele A, De Geeter P, Goebell PJ, Matz U, de Schultz W, Edlich B, Retz M
Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature.
J Clin Oncol. 2015;33 S(7): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Liaw BCH, Chippada-Venkata U, Gong YX, Wang L, Zhu J, Heck MM, Tsao CK, Galsky MD, Oh WK
Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature.
J Clin Oncol. 2015;33 S(15): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Liaw BCH, Chippada-Venkata U, Gong YX, Wang L, Zhu J, Heck MM, Tsao CK, Galsky MD, Oh WK
PET imaging with of prostate-specific membrane antigen (PSMA) for staging of primary prostate cancer with Ga-68-HBED-PSMA.
J Clin Oncol. 2015;33 S(15): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Maurer T, Gschwend J, Wester HJ, Souvatzoglou M, Beer A, Holzapfel K, Weirich G, Haller B, Kubler H, Schwaiger M, Eiber M
PET imaging with (68)Gallium-labelled ligand of prostate-specific membrane antigen (Ga-68-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.
J Clin Oncol. 2015;33 S(15): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Maurer T, Gschwend J, Wester HJ, Souvatzoglou M, Beer A, Holzapfel K, Weirich G, Haller B, Kubler H, Schwaiger M, Eiber M
Association of the prostate cancer risk mutation G84E in HOXB13 with the subtype of ETS fusion negative adenocarcinoma with early age of diagnosis.
J Clin Oncol. 2015;33 S(15): - (Impact(2014)=18.443, Typ=Meeting Abstract)
Schnoeller TJ, Luedeke M, Rinckleb A, Stanford JL, Fitzgerald L, Schleutker J, Wahlfors T, Eeles RA, Kote-Jarai Z, Weikert S, Krause H, Herkommer K, Hoegel J, Maier C
A Phase IIA Dose-Finding Study of PVP-Hypericin Fluorescence Cystoscopy for Detection of Nonmuscle-Invasive Bladder Cancer.
J Endourol. 2015;29(2): 216-22 (Impact(2014)=1.708, Typ=Article; Journal Article)
Straub M, Russ D, Horn T, Gschwend JE, Abrahamsberg C
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
J Immunother Cancer. 2015;3: 26 (Impact: liegt nicht vor, Typ=Journal Article)
Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A
Evaluation of Hybrid ??Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
J Nucl Med. 2015;56(5): 668-74 (Impact(2014)=6.16, Typ=Article; Journal Article; Evaluation Studies; Research Support, Non-U.S. Gov't)
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kübler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M
PET/MRI/TRUS image fusion guided prostate biopsy: development of a research platform and initial clinical results
J Nucl Med. 2015;56 3(3): - (Impact(2014)=6.16, Typ=Meeting Abstract)
Frisch B, Storz E, Zettinig O, Shah A, Kubler H, Navab N, Wester H, Schwaiger M, Eiber M, Maurer T
Freehand SPECT for In-111-PSMA-I&T radioguided lymphadenectomy in prostate cancer patients
J Nucl Med. 2015;56 3(3): - (Impact(2014)=6.16, Typ=Meeting Abstract)
Frisch B, Maurer T, Okur A, Weineisen M, Schottelius M, Kubler H, Navab N, Wester H, Schwaiger M, Eiber M
HIGH PATIENT SATISFACTION AFTER IMPLANTATION OF A 3-PIECE INFLATABLE PENILE PROSTHESIS: CORRELATION OF THE IIEF AND EDITS QUESTIONNAIRE
J Sex Med. 2015;12 1: 90-90 (Impact(2014)=3.151, Typ=Meeting Abstract)
Hatzichristodoulou G, Klorek T, Gschwend J
IMPROVED ERECTILE FUNCTION RECOVERY AFTER NERVE-SPARING RADICAL PROSTATECTOMY BY INK-MARKED INTRAOPERATIVE FROZEN SECTION MONITORING OF THE PROSTATE: RESULTS OF A PROSPECTIVE SINGLE-SURGEON SERIES
J Sex Med. 2015;12 1: 24-25 (Impact(2014)=3.151, Typ=Meeting Abstract)
Hatzichristodoulou G, Wagenpfeil S, Weirich G, Herkommer K, Kubler H, Gschwend J
SURGICAL THERAPY OF PEYRONIES DISEASE BY PARTIAL PLAQUE EXCISION AND GRAFTING WITH COLLAGEN FLEECE: LONG-TERM RESULTS
J Sex Med. 2015;12 2: 126-127 (Impact(2014)=3.151, Typ=Meeting Abstract)
Hatzichristodoulou G, Fiechtner S, Gschwend JE, Lahme S
INTERNATIONAL MULTICENTER PSYCHOMETRIC EVALUATION OF PATIENT REPORTED OUTCOME DATA FOR THE TREATMENT OF PEYRONIES DISEASE
J Sex Med. 2015;12 1: 47-47 (Impact(2014)=3.151, Typ=Meeting Abstract)
Kueronya V, Miernik A, Kojovic V, Hatzichristodoulou G, Egydio P, Tosev G, Falcone M, Djordjevic M, Schoenthaler M, Fahr C, De Luca F, Kuehhas F
Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease.
J Sex Med. 2015;12(12): 2492-8 (Impact(2014)=3.151, Typ=Article; Journal Article; Comparative Study)
Yafi FA, Hatzichristodoulou G, Knoedler CJ, Trost LW, Sikka SC, Hellstrom WJ
SURVIVAL AFTER RADICAL PROSTATECTOMY OR RADIOTHERAPY AS PRIMARY TREATMENT IN PATIENTS WITH NON-METASTASIZED PROSTATE CANCER
J Urol. 2015;193 S(4): E787-E787 (Impact(2014)=4.36, Typ=Meeting Abstract)
Gratzke C, Dorr M, Herkommer K, Oberneder R, Baur H, Beer V, Belka C, Schubert-Fritschle G, Holzel D, Gschwend J, Stief C, Engel J
LONG-TERM RESULTS AFTER PARTIAL PLAQUE EXCISION AND GRAFTING WITH COLLAGEN FLEECE IN PEYRONIES DISEASE
J Urol. 2015;193 S(4): E967-E967 (Impact(2014)=4.36, Typ=Meeting Abstract)
Hatzichristodoulou G, Fiechtner S, Gschwend J, Lahme S
IMPACT OF INTRAOPERATIVE FROZEN SECTIONS OF THE URETHRA ON SURGICAL MARGINS AND ONCOLOGIC OUTCOME IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY
J Urol. 2015;193 S(4): E684-E684 (Impact(2014)=4.36, Typ=Meeting Abstract)
Hatzichristodoulou G, Wagenpfeil S, Herkommer K, Gschwend J
FATAL FAMILY HISTORY OF PROSTATE CANCER AND APPARENT MODE OF DISEASE TRANSMISSION: INDEPENDENT PREDICTORS OF RADICAL PROSTATECTOMY OUTCOMES?
J Urol. 2015;193 S(4): E658-E658 (Impact(2014)=4.36, Typ=Meeting Abstract)
Herkommer K, Heister S, Gschwend J, Kron M
DETECTION RATES OF 68GALLIUM-LABELLED LIGAND OF PSMA PET/CT AND PET/MRI IN 332 CONSECUTIVE PATIENTS WITH BIOCHEMICAL RECURRENCY AFTER RADICAL PROSTATECTOMY
J Urol. 2015;193 S(4): E706-E706 (Impact(2014)=4.36, Typ=Meeting Abstract)
Maurer T, Beck V, Beer A, Souvatzoglou M, Holzapfel K, Kubler H, Gschwend JE, Wester HJ, Haller B, Schwaiger M, Eiber M
PREOPERATIVE LYMPH NODE STAGING IN INTERMEDIATE TO HIGH-RISK PROSTATE CANCER PATIENTS USING 68GA-HBED-PSMA PET HYBRID IMAGING - A PATIENT- AND FIELD-BASED ANALYSIS
J Urol. 2015;193 S(4): E707-E707 (Impact(2014)=4.36, Typ=Meeting Abstract)
Maurer T, Pahr L, Souvatzoglou M, Weirich G, Kubler H, Wester HJ, Haller B, Schwaiger M, Gschwend JE, Eiber M
PSMA-RADIOGUIDED SURGERY: INTRODUCING MOLECULAR SURGERY IN PATIENTS WITH RECURRENT PROSTATE CANCER
J Urol. 2015;193 S(4): E1040-E1041 (Impact(2014)=4.36, Typ=Meeting Abstract)
Maurer T, Weineisen M, Wester HJ, Schottelius M, Okur A, Weirich G, Kubler H, Schwaiger M, Gschwend JE, Frisch B, Eiber M
PEYRONIES DISEASE FOLLOWING RADICAL PROSTATECTOMY: INCIDENCE IN A POPULATION WITH FORMAL PRE OPERATIVE ASSESSMENT
J Urol. 2015;193 S(4): E966-E966 (Impact(2014)=4.36, Typ=Meeting Abstract)
Sullivan J, Tal R, Heck M, Bernstein M, Nelson C, Mulhall J
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol. 2015;16(4): 417-25 (Impact(2014)=24.69, Typ=Article; Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't)
Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Lancet Oncol. 2015;16(2): 152-60 (Impact(2014)=24.69, Typ=Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; Comparative Study)
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators , Boyce A, Costello A, Davis I, Ganju V, Horvath L, Lynch R, Mainwaring P, Marx G, Ng S, Parnis F, Shapiro J, Singhal N, Slancar M, Van Hazel G, Wong S, Yip SD, Carpentier P, Luyten D, Rottey S, Schrijvers D, Van Aelst F, Van Poppel H, Cheng T, Chin J, Ellard S, Fradet Y, Gleave M, Joshua A, Klotz L, Martins H, Mukherjee S, North S, Winquist E, Abdel-Hamid S, Colombel M, Fléchon A, Haillot O, Joly F, Oudard S, Priou F, Raymond E, Albers P, Boegemann M, Gleissner J, Gschwend J, Hammerer P, Heidenreich A, Kuczyk M, Miller K, Oetzel R, Roigas J, Steuber T, Stöckle M, Suttman H, Wirth M, Efstathiou E, Papandreou C, Bracarda S, Marcello T, Sternberg C, Bangma C, Gerritsen W, Arranz Arija J, Bellmunt J, Lopez R, Lopez-Brea M, Piulats J, Bjartell A, Damber J, Haggman M, Hellstrom M, Seke M, Brown J, Chowdhury S, de Bono J, Elliott T, Harland S, Innes H, James N, Jones R, Mazhar D, Paez E, Protheroe A, Staffurth J, Ahmann F, Andriole G, Arrowsmith E, Assikis V, Baron A, Basch E, Berry W, Bubley G, Carney J, Chu L, Cosgriff T, Denmeade S, Deshpande H, Duchene D, Estathiou E, Ferrari A, Frenkel E, Gabrail N, Garcia J, George D, Gomella L, Goodman O, Gore I, Gullo J, Hainsworth J, Hamid O, Hutson T, King D, Koh H, Koletsky A, Kudrik F, Lara P, Lyons R, Maranchie J, Modiano M, Nieva J, Nordquist L, Pantuck A, Pinski J, Polesz B, Polikoff J, Quinn D, Redfern C, Riggs S, Ryan C, Saleh M, Sartor A, Scher H, Scholz M, Shore N, Srinivas S, Vaishampaya U, Vieweg J, Vira M, Vogelzang N, Wilding G, Wong Y, Yu E
Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-?-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
Mol Imaging Biol. 2015;17(2): 248-56 (Impact(2014)=2.774, Typ=Article; Journal Article)
Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015;373(19): 1814-23 (Impact(2014)=55.873, Typ=Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; Comparative Study)
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators , Tan H, Hovey E, Mainwaring P, Steer C, Marx G, deSouza P, Davis I, Begbie S, Nott L, Pook D, Cuff K, Epstein R, Gurney H, Schmidinger M, Loidl W, De Santis M, Gil T, Wynendaele W, Demey W, Schöffski P, Knox J, Soulieres D, Czaykowski P, Basappa N, Kollmannsberger C, Bjarnason G, Wood L, Zalewski P, Hotte S, Heng D, Winquist E, Salman P, Frontera O, Katolicka J, Melichar B, Jensen N, Geertsen P, Donskov F, Peltola K, Escudier B, Gravis G, Joly F, Chevreau C, Oudard S, Laguerre B, Rolland F, Voog E, Negrier S, Maurina T, Goupil M, Staehler M, Pfister D, Rink M, Gruenwald V, Retz M, Wirth M, Schultze-Seemann W, Depenbusch R, Schnöller T, Bergmann L, Gruellich C, Csoszi T, Geczi L, McCaffrey J, McDermott R, Sternberg C, Passalacqua P, De Giorgi U, Sabbatini R, Boccardo F, Carrozza F, Roila F, Santini D, Bracarda S, van Thienen J, Aarts M, Osanto S, Tomczak P, Pikiel J, Wojtukiewicz M, Szczylik C, Sousa N, Coelho J, Costa L, Cheporov S, Kopyltsov E, Nosov D, Mincik I, Mikulas J, Rha S, Keam B, Lee J, Park S, Grande E, Chirivella I, Solans XG, Suarez C, Duran I, Castellano D, Garcia Donas J, Perez Gracia J, Martinez A, Medina M, Maroto P, Gonzalez E, Harmenberg U, Thomasson M, Blom R, Lin C, Chang Y, Ou Y, Sevinc A, Dane F, Gokmen E, Yildiz R, Hawkins R, Hussain S, Larkin J, Nathan P, Porfiri E, Malik J, MacDonald A, Powles T, Chowdhury S, Glen H, Motzer R, Choueiri T, Geynisman D, Kluger H, Appleman L, Shaffer D, Fishman M, Hainsworth J, Sonpavde G, Drabkin H, Hammers H, George D, Merchan J, Hussain A, Koletsky A, Hanna W, Troner M, Vaishampayan U, Costello B, Olencki T, Vaena D, Redman B, Rini B, Stadler W, Roth B, Tannir N, Kuzel T, Wright J, Hutson T, Van Veldhuizen P, Richey S, Doshi G, Sarantopoulos J, Ryan C, Samlowski W, Tykodi S, Pal S, Agarwal N, Kabbinavar F, Figlin R, Ho T, Wong B, Singh P, Kolevska T, Randall J
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015;373(19): 1803-13 (Impact(2014)=55.873, Typ=Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't; Comparative Study)
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate 025 Investigators , Korbenfeld E, Palazzo FS, Recondo G, Chacon M, Richardet ME, Susana M, Pook D, Toner G, Gurney H, Davis I, Pittman KB, Kavina A, Schmidinger M, Loidl W, Schallier D, Machiels JP, Schoffski P, Rottey S, Dzik C, Schutz F, Franke FA, Kollmannsberger CK, Heng D, Knox J, Wood L, Basappa N, Zalewski P, Ghedira S, Miller W, Melichar B, Kubala E, Prausova J, Donskov F, Jensen NV, Geertsen P, Bono P, Ravaud A, Escudier B, Chevreau C, Rolland F, Gravis G, Tourani JM, Geoffrois L, Oudard S, Heidenreich A, Imkamp F, Bedke J, Meiler J, Retz M, Goebell P, Pahernik S, Bamias A, Papazsis K, McCaffrey JA, McDermott R, Neumann A, Berger R, Neiman V, Santoro A, Sternberg C, Roila F, Procopio G, Maio M, Bracarda S, De Giorgi U, Hongo F, Kimura G, Kanayama H, Kitamura H, Kume H, Uemura H, Yonese J, Tanabe K, Tatsugami K, Eto M, Oya M, Saito M, Uemura M, Yao M, Shinohara N, Yamaguchi R, Fukasawa S, Kato T, Sugiyama T, Obara W, Heinrich D, Straume O, Szcylik C, Slomian G, Wojcik-Tomaszewska J, Tomczak P, Zdrojowy R, Volovat C, Lungulescu D, Sinescu I, Poddubskaya E, Karlov P, Matveev V, Suarez C, Castellano D, Puente J, Arranz JA, Perez Gracia JL, Del Muro X, Jellvert A, Harmenberg U, Wagstaff J, Gore M, Nathan P, Eisen T, Alva A, Amin A, Carthon B, McDermott D, Quinn D, Vaena D, Lam E, Plimack E, Millard F, Quddus F, Beltran H, Drabkin H, Hammers HJ, Brugarolas J, Clark J, Hainsworth J, Sarantopoulos J, Sosman J, Beck JT, Fong L, Fishman M, Harrison M, Dawson N, Sharma P, Figlin R, Motzer R, George S, Srinivas S, Tykodi S, Kuzel T, Logan T, Olencki T, Vaishampayan U, Voelzke W
Trials in progress: The influence of the therapy sequence in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Cabazitaxel - the international, prospective non-interventional trial SCOPE
ONCOLOGY RESEARCH AND TREATMENT. 2015;38 5: 81-82 (Impact(2014)=0, Typ=Meeting Abstract)
Bokemeyer C, Stoiber F, Amram ML, Gschwend JE
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
Oncology. 2015;89(2): 70-8 (Impact(2014)=2.422, Typ=Article; Journal Article; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't)
Niegisch G, Retz M, Thalgott M, Balabanov S, Honecker F, Ohlmann CH, Stöckle M, Bögemann M, Vom Dorp F, Gschwend J, Hartmann A, Ohmann C, Albers P
Prediction of individual genetic risk to prostate cancer using a polygenic score.
Prostate. 2015;75(13): 1467-74 (Impact(2014)=3.565, Typ=Article; Journal Article)
Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai ZS, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubi?ski J, Klu?niak W, Cannon-Albright L, Brenner H, Butterbach K, Stegmaier C, Park JY, Sellers T, Lin HY, Lim HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Australian Prostate Cancer BioResource , Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Practical Consortium , Gronberg H, Wiklund F, Cook M, Guy M, Govindasami K, Leongamornlert D, Sawyer EJ, Wilkinson R, Saunders EJ, Tymrakiewicz M, Dadaev T, Morgan A, Fisher C, Hazel S, Livni N, Lophatananon A, Pedersen J, Hopper JL, Adolfson J, Stattin P, Johansson JE, Cavalli-Bjoerkman C, Karlsson A, Broms M, Auvinen A, Kujala P, Maeaettaenen L, Murtola T, Taari K, Weischer M, Nielsen SF, Klarskov P, Roder A, Iversen P, Wallinder H, Gustafsson S, Cox A, Brown P, George A, Marsden G, Lane A, Davis M, Zheng W, Signorello LB, Blot WJ, Tillmans L, Riska S, Wang L, Rinckleb A, Lubiski J, Stegmaier C, Park H, Radlein S, Rincon M, Haley J, Zachariah B, Kachakova D, Popov E, Mitkova A, Vlahova A, Dikov T, Christova S, Srinivasan S, Kedda MA, Risbridger G, Tilley W, Horvath L, Wu H, Henrique R, Pinto P, Santos J, Barros-Silva J, Kolb S, Karyadi DM
Non-invasive differentiation of kidney stone types using X-ray dark-field radiography.
Sci Rep. 2015;5: 9527 (Impact(2014)=5.578, Typ=Article; Journal Article; Research Support, Non-U.S. Gov't)
Scherer K, Braig E, Willer K, Willner M, Fingerle AA, Chabior M, Herzen J, Eiber M, Haller B, Straub M, Schneider H, Rummeny EJ, Noël PB, Pfeiffer F
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.
Semin Cancer Biol. 2015;35 Suppl: S25-54 (Impact(2014)=9.33, Typ=Review; Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural)
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S
Integration of PSMA-PET Imaging in the Radiation Treatment Planning- primary definitive Radiotherapy in Prostate Cancer
Strahlenther Onkol. 2015;191 1: S56-S56 (Impact(2014)=2.914, Typ=Meeting Abstract)
Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend JE, Combs SE, Habl G
Evaluation of PSMA-PET for diagnosis of Recurrence in Patients with Prostate Cancer after Prostatectomy and Integration of PSMA-PET Imaging in Radiotherapy Planning
Strahlenther Onkol. 2015;191 1: S50-S51 (Impact(2014)=2.914, Typ=Meeting Abstract)
Sauter K, Eiber M, Maurer T, Vogel MME, Heidger A, Kessel KA, Schwaiger M, Gschwend JE, Combs SE, Habl G
Health-related quality of life after radical prostatectomy depends on patient's age but not on comorbidities.
Urol Oncol. 2015;33(6): 266.e1-7 (Impact(2014)=2.768, Typ=Journal Article)
Herkommer K, Schmid SC, Schulwitz H, Dinkel A, Klorek T, Hofer C, Ehrl D, Blaser R, Gschwend JE, Kron M
[Non-muscle-invasive high-grade bladder cancer].
Urologe A. 2015;54(4): 491-8 (Impact(2014)=0.444, Typ=Article; Journal Article; English Abstract)
Gakis G, Stenzl A, Horn T, Gschwend JE, Otto W, Burger M
[Conservative therapy of Peyronie's disease - update 2015].
Urologe A. 2015;54(5): 641-7 (Impact(2014)=0.444, Typ=Article; Journal Article; Review; English Abstract)
Hatzichristodoulou G
[Sexuality of couples 5 years after radical prostatectomy. Sexuality of patients and their partners 1 year postoperatively in sexually active couples].
Urologe A. 2015;54(10): 1407-13 (Impact(2014)=0.444, Typ=Article; Journal Article; English Abstract)
Jordan TB, Ernst R, Hatzichristodoulou G, Dinkel A, Klorek T, Beyrle C, Gschwend JE, Herkommer K
[Erratum to: Positron-emission tomography in urooncology].
Urologe A. 2015;54(9): 1293 (Impact(2014)=0.444, Typ=Correction; Published Erratum)
Maurer T, Kübler H, Gschwend JE, Eiber M
[Inguinal lymphadenectomy in penile cancer: Study for prevention of wound complications after inguinal lymphadenectomy in patients with penile cancer by epidermal vacuum therapy (PräVAC, EUDAMED: CIV-12-07-008204; DRKS-ID: DRKS00005257)].
Urologe A. 2015;54(12): 1799-801 (Impact(2014)=0.444, Typ=Editorial Material; Journal Article)
Maurer T, Seitz AK, Schneider S, Protzel C, Retz M, Rexer H, Geschäftsstelle der AUO
[Positron-emission tomography in urooncology].
Urologe A. 2015;54(7): 983-91 (Impact(2014)=0.444, Typ=Article; Journal Article; English Abstract)
Maurer T, Kübler H, Gschwend JE, Eiber M
[Combined chemohormonal therapy for metastatic hormone-sensitive prostate cancer : Effectiveness and update as a joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Urologe A. 2015;54(11): 1606-8 (Impact(2014)=0.444, Typ=Article; Journal Article)
Ohlmann CH, Gschwend J, Miller K, Mitglieder von AKO und die Vorstandsmitglieder der AUO
[Sexuality after radical prostatectomy: Evaluation of erectile function and patient counseling regarding their sex life].
Urologe A. 2015;54(5): 696-702 (Impact(2014)=0.444, Typ=Article; Journal Article; Clinical Trial; English Abstract)
Schmidtke ML, Dinkel A, Gschwend JE, Herkommer K
[Imaging in urology].
Urologe A. 2015;54(7): 947 (Impact(2014)=0.444, Typ=Editorial Material; Introductory Journal Article)
Stief CG, Gschwend JE
[Diagnostic imaging of urolithiais. Current recommendations and new developments].
Urologe A. 2015;54(7): 948-55 (Impact(2014)=0.444, Typ=Article; Journal Article; Review; English Abstract)
Thalgott M, Kurtz F, Gschwend JE, Straub M
Editorial comment.
Urology. 2015;85(2): 450-1 (Impact(2014)=2.188, Typ=Editorial Material; Comment; Editorial)
Kübler HR
Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent.
World J Urol. 2015;33(6): 813-9 (Impact(2014)=2.666, Typ=Article; Journal Article)
Horn T, Schmid SC, Seitz AK, Grab J, Wolf P, Haller B, Retz M, Maurer T, Autenrieth M, Kübler HR, Gschwend JE

2014

Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Røder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokołorczyk D, Kluźniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Breast and Prostate Cancer Cohort Consortium (BPC3) , PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium , COGS (Collaborative Oncological Gene-environment Study) Consortium , GAME-ON/ELLIPSE Consortium , Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
Nat Genet. 2014;46(10): 1103-9
Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE
Treatment algorithm for metastatic renal cell carcinoma - recommendations based on evidence and clinical practice.
Oncol Res Treat. 2014;37(3): 136-41
Boehm J, Eichhorn S, Kornek M, Hauner K, Prinzing A, Grammer J, Lahm H, Wagenpfeil S, Lange R
Apolipoprotein E genotype, TNF-a 308G/A and risk for cardiac surgery associated-acute kidney injury in Caucasians.
Ren Fail. 2014;36(2): 237-43
Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Eur Urol. 2014;
Dinkel A, Kornmayer M, Gschwend JE, Marten-Mittag B, Herschbach P, Herkommer K
Influence of family history on psychosocial distress and perceived need for treatment in prostate cancer survivors.
Fam Cancer. 2014;13(3): 481-8
Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer.
Abdom Imaging. 2014;
Escudier B, Grunwald V, Ravaud A, Ou YC, Castellano D, Lin CC, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi MM, Angevin E
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer.
Clin Cancer Res. 2014;20(11): 3012-22
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
J Clin Oncol. 2014;32(14): 1412-8
Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B
Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe.
Eur Urol. 2014;
Grosu AL, Weirich G, Wendl C, Prokic V, Kirste S, Geinitz H, Souvatzoglou M, Gschwend JE, Schwaiger M, Molls M, Weber WA, Treiber U, Krause BJ
(11)C-Choline PET/pathology image coregistration in primary localized prostate cancer.
Eur J Nucl Med Mol Imaging. 2014;41(12): 2242-8
Heck MM, Gschwend JE
Molecular diagnostics and molecular staging: new developments on the way to daily clinical practice?.
Urologe A. 2014;53(4): 467-8
Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Mollenhauer M, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R
Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Eur Urol. 2014;66(2): 222-9
Heck MM, Retz M, Nawroth R
Molecular lymph node staging in prostate and bladder cancer.
Urologe A. 2014;53(4): 484-90
Heck MM, Souvatzoglou M, Retz M, Nawroth R, Kübler H, Maurer T, Thalgott M, Gramer BM, Weirich G, Rondak IC, Rummeny EJ, Schwaiger M, Gschwend JE, Krause B, Eiber M
Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [(11)C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.
Eur J Nucl Med Mol Imaging. 2014;41(4): 694-701
Herkommer K, Heimpel M, Gschwend JE
[Familial prostate cancer research: meaningfulness of hereditary criteria in view of demographic change].
Urologe A. 2014;53(12): 1779-85
Horn T, Ladwein B, Maurer T, Redlin J, Seitz AK, Gschwend JE, Retz M, Kübler HR
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer.
World J Urol. 2014;32(2): 359-63
Horn T, Schmid SC, Seitz AK, Grab J, Wolf P, Haller B, Retz M, Maurer T, Autenrieth M, Kübler HR, Gschwend JE
Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent.
World J Urol. 2014
Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N
Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
PLoS ONE. 2014;9(11): e112318
Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
BJU Int. 2014;113(3): 429-36
Kueronya V, Miernik A, Stupar S, Kojovic V, Hatzichristodoulou G, Egydio P, Tosev G, Falcone M, De Luca F, Mulalic D, Djordjevic M, Schoenthaler M, Fahr C, Kuehhas F
International multicenter psychometric evaluation of patient reported outcome data for the treatment of Peyronie's disease.
BJU Int. 2014;
Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W
Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
Prostate. 2014;74(14): 1444-51
Maurer T, Beer AJ, Wester HJ, Kübler H, Schwaiger M, Eiber M
Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging?
Int J Urol. 2014;21(12): 1286-8
Maurer T, Eiber M, Krause BJ
Molecular multimodal hybrid imaging in prostate and bladder cancer.
Urologe A. 2014;53(4): 469-83
Maurer T, Gschwend JE
In Process Citation.
Aktuelle Urol. 2014;45(6): 502-7
Maurer T, Horn T, Souvatzoglou M, Eiber M, Beer AJ, Heck MM, Haller B, Gschwend JE, Schwaiger M, Treiber U, Krause BJ
Prognostic value of 11C-choline PET/CT and CT for predicting survival of bladder cancer patients treated with radical cystectomy.
Urol Int. 2014;93(2): 207-13 (Impact(2013)=1.151, Typ=Journal Article)
Maurer T, Protzel C, Gschwend JE, Rexer H, Geschäftsstelle der AUO
Inguinal lymphadenectomy for penile cancer: study on the prevention of wound healing complications.
Urologe A. 2014;53(4): 561-2
Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
J Clin Oncol. 2014;32(2): 76-82
Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Aktuelle Urol. 2014;45(1): 39-44
Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ
Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012.
Urol Oncol. 2014;32(7): 1049-50
Nawroth R, Weckermann D, Retz M
Prostate and bladder cancer: detection of disseminated tumor cells in bone marrow.
Urologe A. 2014;53(4): 514-8
Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.
Br J Cancer. 2014;111(11): 2103-13
Schmid SC, Berberat PO, Gschwend JE, Autenrieth ME
Hands-on teaching for students in urology : The use of peer teaching and simulators.
Urologe A. 2014;53(4): 537-41
Schmid SC, Geith A, Böker A, Tauber R, Seitz AK, Kuczyk M, von Klot C, Gschwend JE, Merseburger AS, Retz M Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Adv Ther. 2014;31(2): 234-41
Schmid SC, Gschwend JE, Retz M
Pharmaceutical treatment of advanced urinary bladder cancer: new developments in 2014.
Urologe A. 2014;53(10): 1535-42
Schmid SC, Gschwend JE, Retz M, Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft e. V. (AUO) [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].
Aktuelle Urol. 2014;45(1): 55-63; quiz 64-5
Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ
Comparison of [(11)C]Choline ([ (11)C]CHO) and S(+)-β-Methyl-[ (11)C]Choline ([ (11)C]SMC) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Mol Imaging Biol. 2014
Seitz AK, Protzel C, Retz M, Arbeitsgemeinschaft Urologische Onkologie (AUO) der Deutschen Krebsgesellschaft e. V
Current state of chemotherapy in treatment of advanced penile cancer.
Aktuelle Urol. 2014;45(4): 286-92
Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C
Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: EAU Guidelines.
Eur Urol. 2014;
Thalgott M, Heck MM, Pantel K
Detection of circulating tumor cells from peripheral blood in prostate cancer.
Urologe A. 2014;53(4): 509-13
Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, Autenrieth M, Herkommer K, Krause BJ, Gschwend JE, Treiber U, Kübler HR
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
J Hematol Oncol. 2014;7(1): 20
Vag T, Heck MM, Beer AJ, Souvatzoglou M, Weirich G, Holzapfel K, Krause BJ, Schwaiger M, Eiber M, Rummeny EJ
Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT.
Eur Radiol. 2014;
von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS
Is there an anti-androgen withdrawal syndrome for enzalutamide?
World J Urol. 2014;
Wieser A, Storz E, Liegl G, Peter A, Pritsch M, Shock J, Wai SN, Schubert S
Efficient quantification and characterization of bacterial outer membrane derived nano-particles with flow cytometric analysis.
Int J Med Microbiol. 2014;304(8): 1032-7
Wirth M, Heidenreich A, Gschwend JE, Gil T, Zastrow S, Laniado M, Gerloff J, Zühlsdorf M, Mordenti G, Uhl W, Lannert H
A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting av Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After Chemotherapy.
Eur Urol. 2014;65(5): 897-904
Zengerling F, Hartmann M, Heidenreich A, Krege S, Albers P, Karl A, Weissbach L, Wagner W, Bedke J, Retz M, Schmelz HU, Kliesch S, Kuczyk M, Winter E, Pottek T, Dieckmann KP, Schrader AJ, Schrader M, GTCSG (German Testicular Cancer Study Group)
German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice.
Oncol Rep. 2014;31(6): 2477-81

2013

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology , UK ProtecT Study Collaborators , Australian Prostate Cancer Bioresource , PRACTICAL Consortium , Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
Hum Mol Genet. 2013;22(2): 408-15
Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Clin Cancer Res. 2013;19(5): 1257-68
Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, Kübler H, Maurer T, Gschwend JE, Geinitz H, Grosu AL, Ziegler SI, Krause BJ
Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.
Eur J Nucl Med Mol Imaging. 2013;40(6): 824-31
Gschwend J
Rational medical therapy for tumors.
Urologe A. 2013;52(11): 1515-6
Hatzichristodoulou G, Dorstewitz A, Gschwend JE, Herkommer K, Zantl N
Surgical management of penile fracture and long-term outcome on erectile function and voiding.
J Sex Med. 2013;10(5): 1424-30
Hatzichristodoulou G, Gschwend JE, Lahme S
Surgical therapy of Peyronie's disease by partial plaque excision and grafting with collagen fleece: feasibility study of a new technique.
Int J Impot Res. 2013;25(5): 183-7
Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S
Extracorporeal Shock Wave Therapy in Peyronie's Disease: Results of a Placebo-Controlled, Prospective, Randomized, Single-Blind Study.
J Sex Med. 2013;10(11): 2815-21
Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Eur Urol. 2013;63(6): 977-82
Horn T, Grab J, Schusdziarra J, Schmid S, Maurer T, Nawroth R, Wolf P, Pritsch M, Gschwend JE, Kübler HR, Beckhove P
Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.
Int J Cancer. 2013;133(9): 2145-56
Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Müller-Mattheis V, Grimm MO, Gschwend JE, Wülfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
Invest New Drugs. 2013;31(4): 1001-7
Keck B, Merseburger AS, Stöhr R, Füssel S, Hoffmann MJ, Schmid S, Olbert P, Hartmann A, Nawroth R
Bladder cancer in focus: update 2012 of the German Bladder Cancer Association.
Urologe A. 2013;52(3): 373-7
Koch W, Mueller JC, Schrempf M, Wolferstetter H, Kirchhofer J, Schömig A, Kastrati A
Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene.
Ann Hum Genet. 2013;77(1): 47-55
Kübler H, Miller K
New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy.
Urologe A. 2013;52(11): 1517-8, 1520-1, 1524-6 pa
Maurer T, Horn T, Beer AJ, Eiber M, Gschwend JE
Functional imaging in bladder cancer.
Urologe A. 2013;52(4): 509-14
Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M, Wirth M
Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma.
Aktuelle Urol. 2013;44(1): 45-9
Protzel C, Seitz AK, Hakenberg OW, Retz M
Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer.
Urologe A. 2013;52(11): 1556-60, 1562-3
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators , Boyce A, Costello A, Davis I, Ganju V, Horvath L, Lynch R, Marx G, Parnis F, Shapiro J, Singhal N, Slancar M, Van Hazel G, Wong S, Yip D, Carpentier P, Luyten D, Rottey S, Van Aelst F, Cheng T, Chin J, Ellard S, Fradet Y, Gleave M, Joshua A, Klotz L, Martins H, North S, Abdel-Hamid S, Colombel M, Fléchon A, Haillot O, Joly F, Oudard S, Priou F, Raymond E, Albers P, Boegemann M, Gleissner J, Gschwend J, Hammerer P, Heidenreich A, Kuczyk M, Miller K, Oetzel R, Roigas J, Steuber T, Stöckle M, Wirth M, Papandreou C, Bracarda S, Marcello T, Sternberg C, Bangma C, de Reijke T, Arija J, Bellmunt J, Lopez R, Lopez-Brea M, Bjartell A, Damber J, Haggman M, Hellstrom M, Seke M, Brown J, Chowdhury S, Elliott T, Harland S, Innes H, James N, Jones R, Mazhar D, Paez E, Protheroe A, Staffurth J, Ahmann F, Andriole G, Arrowsmith E, Assikis V, Baron A, Berry W, Bubley G, Carney J, Chu L, Cosgriff T, Denmeade S, Deshpande H, Duchene D, Ferrari A, Frenkel E, Gabrail N, Garcia J, George D, Gomella L, Goodman O, Gore I, Gullo J, Hainsworth J, Hamid O, Hutson T, King D, Koh H, Koletsky A, Kudrik F, Lara P, Lyons R, Maranchie J, Modiano M, Nieva J, Nordquist L, Pinski J, Poiesz B, Polikoff J, Quinn D, Redfern C, Riggs S, Ryan C, Saleh M, Sartor A, Scholz M, Shore N, Srinivas S, Vaishampaya U, Vieweg J, Vira M, Vogelzang N, Wilding G, Wong Y, Belldegrun A, Kantoff PW, Carducci MA, Vogelzang NJ, Kelly WK, Auchus RJ, Meyers M, Rackoff W, Tran N, Yu M, Knoblauch R, Naini V, Matheny S, Maul S, Larsen J, Martin J, Wawda H, Goffredo D, Li J, Li S, Li B, Durve K, Morris MJ, Larson SM
Abiraterone in metastatic prostate cancer without previous chemotherapy.
N Engl J Med. 2013;368(2): 138-48
Schmid SC, Schuster T, Horn T, Gschwend J, Treiber U, Weirich G
Utility of ATP7B in Prediction of Response to Platinum-based Chemotherapy in Urothelial Bladder Cancer.
Anticancer Res. 2013;33(9): 3731-7
Schwarzenböck S, Sachs D, Souvatzoglou M, Schuster T, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Krause BJ
[11C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model.
Nuklearmedizin. 2013;52(4): 141-7
Souvatzoglou M, Eiber M, Takei T, Fürst S, Maurer T, Gaertner F, Geinitz H, Drzezga A, Ziegler S, Nekolla SG, Rummeny EJ, Schwaiger M, Beer AJ
Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.
Eur J Nucl Med Mol Imaging. 2013;40(10): 1486-99
Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ, RECORD-1 Trial Study Group , Davis I, Gurney H, Pittman K, Goldstein D, Mainwaring P, Knox J, Ades S, Cheng T, Hotte S, Ko YJ, MacKenzie M, North S, Escudier B, Oudard S, Ravaud A, Caty A, Rolland F, Chevreau C, Duclos B, Negrier S, Grünwald V, Gschwend J, Albers P, Bergmann L, Beck J, Porta C, Bracarda S, Conte P, Bajetta E, Passalacqua R, Sternberg C, Boccardo F, Carteni G, Akaza H, Uemura H, Shinohara N, Tsuchiya N, Fujimoto H, Niwakawa M, Kanayama H, Eto M, Sumiyoshi Y, Tsukamoto T, Usami M, Terai A, Hamamoto Y, Maruoka M, Osanto S, Van Herpen C, Van Den Eertwegh F, Groenewegen G, Szczylik C, Pikiel J, Pluzanska A, Zdrojowy R, Calvo E, del Muro F, Climent M, Castellano D, Maroto P, Motzer R, Hutson T, Thompson J, Figlin R, Gabrail N, Appleman L, George D, Hamm J, Hussain A, Hajdenberg J, Vogelzang N, Logan T, Beck J, Rathmell K, Lara P, Dudek A, Vaishampayan U, Gordon M, Anderson T, Danso M, Berry W, Gersh R, Guzley G, Loesch D, Schlossman D, Smith D, Alemany C
Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
Eur Urol. 2013;64(6): 994-1002
Straub M, Bader M, Strittmatter F
Management of ureteral stones.
Urologe A. 2013;52(3): 415-26
Tauber R, Schmid S, Horn T, Thalgott M, Heck M, Haller B, Kübler H, Autenrieth M, Retz M, Gschwend JE, Maurer T
Inguinal lymph node dissection: Epidermal vacuum therapy for prevention of wound complications.
J Plast Reconstr Aesthet Surg. 2013;66(3): 390-6)
Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kreß V, Heck MM, Andergassen U, Nawroth R, Gschwend JE, Retz M
Detection of circulating tumor cells in different stages of prostate cancer.
J Cancer Res Clin Oncol. 2013;139(5): 755-63